Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus

Completed

Conditions studied: End Stage Renal Disease

In brief

The purpose of this study is to learn if conversion from immediate release tacrolimus to Envarsus improves cerebral blood flow, brain blood flow response to exercise, and cognition.

Key facts

Study ID

NCT03703154

Run by

University of Kansas Medical Center

People needed

30

Starts

2018-10-25

Expected to finish

2021-03-03

Last updated by the study team

2021-04-27

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age between 18 and 85 years
• English speaking (NP tests will be in English);
• able to sign informed consent
• able to arrange transportation to and from study sites
• without acute stroke, concussion or traumatic brain injury
• received a kidney transplant at least 12 weeks before recruitment
• stable kidney function with serum creatinine <3mg/dl

You may not qualify if…

• are claustrophobic or have other contra-indication for MRI
• have hearing or visual impairment
• are unable to read, write, speak or understand English
• have uncontrolled psychosis or seizure disorder or are currently using antipsychotics or anti-epileptics
• dual organ transplant
• oxygen-dependent chronic obstructive pulmonary disease
• diagnosis of dementia
• unable to perform exercise on the Nustep (muscle weakness or cardiac safety concern)
• uncontrolled blood pressure

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.